SCHEMBL5136808

SCHEMBL5136808

CCCCN(Cc1ccc2c(c1)OCCO2)Cc1c(-c2ccccc2OC)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.53
F2R P25116 1/20 0.39
HTR2B P41595 9/20 0.37
HTR2C P28335 8/20 0.37
HTR2A P28223 8/20 0.37
DRD2 P14416 3/20 0.36
DRD3 P35462 3/20 0.36
HTR1A P08908 2/20 0.36
ADRB1 P08588 1/20 0.36
ADRA2A P08913 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
DRD1 P21728 1/20 0.36
DRD4 P21917 1/20 0.36
SLC6A2 P23975 1/20 0.36
ADRA1D P25100 1/20 0.36
HTR1D P28221 1/20 0.36
SLC6A4 P31645 1/20 0.36
HTR7 P34969 1/20 0.36
ADRA1A P35348 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135009 0.95 C5AR1 (0.60) C5AR1F2RHTR2BHTR2CHTR2A
SCHEMBL649820 0.91 C5AR1 (0.62) C5AR1F2RHTR2BHTR2CHTR2A
SCHEMBL5135936 0.89 C5AR1 (0.63) C5AR1LMNASMN1; SMN2L3MBTL1TSHR
SCHEMBL4766754 0.89 C5AR1 (0.57) C5AR1F2RHTR2BHTR2CHTR2A
SCHEMBL5135904 0.88 C5AR1 (0.56) C5AR1F2RTP53LMNASMN1; SMN2
SCHEMBL5071329 0.87 C5AR1 (0.60) C5AR1TP53LMNASMN1; SMN2L3MBTL1
SCHEMBL648955 0.86 C5AR1 (0.58) C5AR1OPRM1LMNASMN1; SMN2L3MBTL1
SCHEMBL5073846 0.86 C5AR1 (0.58) C5AR1F2RLMNASMN1; SMN2L3MBTL1
SCHEMBL5135734 0.86 C5AR1 (0.63) C5AR1F2RLMNASMN1; SMN2L3MBTL1
SCHEMBL5136554 0.86 C5AR1 (0.58) C5AR1F2RLMNASMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed